Lundbeck hands over former Alzheimer's candidate to privately-owned biotech company
Lundbeck is giving idalopirdine, which it shelved in 2017 following disappointing results for Alzheimer's disease, to Denovo Biopharma, which has in-licensed rights to all indications.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Denovo Biopharma appears to think that Lundbeck's hand-me-downs are quite the treasure trove.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Amgen gets Japanese authorization for migraine drug
For subscribers
